Should employers cover GLP-1 drugs for obesity?

Drugs like Ozempic could prove costly for benefit plans – but also mean healthier employees

Should employers cover GLP-1 drugs for obesity?

“Ozempic” filled many headlines in 2023, as the GLP-1 drug has proven effective and popular when it comes to weight loss – despite its original mandate being focused on diabetes.

To read the full story, login below.

Not a subscriber?

Start your subscription today!